Robust lentiviral manufacturing platforms in the age of accessible cell therapy

Brought to you by the team at:

What readers will learn:

• Why lentiviral vector manufacturing remains a critical bottleneck for scalable, accessible cell therapies
• The limitations of traditional CDMO models when applied to lentiviral development
• How platformed, modular vector manufacturing can reduce cost, timelines, and development risk
• The role of early construct optimization in achieving commercially viable vector yields
• How ready-to-deploy and custom LV strategies can coexist within a single manufacturing framework

More about this whitepaper:

Lentiviral vectors are foundational to the success of gene-modified cell therapies, yet their development and manufacture remain complex, costly, and difficult to scale. As cell therapies move toward broader patient access and decentralized manufacturing models, traditional approaches to lentiviral production are increasingly misaligned with clinical and commercial realities.

Drawing on decades of lentiviral development experience and supported by a fully characterized manufacturing process, this paper explores why platforming lentiviral manufacturing is essential for advancing next-generation cell and gene therapies from concept to clinic and, ultimately, to patients worldwide.